Hunt joins the company from HeartBeam.
Jon Hunt, PhD, is joining Implicity as chief commercial officer.
Previously, Hunt worked for HeartBeam, a cardiac technology company, as an executive vice president and chief business officer. He has worked in the cardiovascular device industry for nearly 40 years.
In a press release, CEO and co-founder of Implicity Arnaud Rosier, MD, PhD, said, “Having an executive of Jon's caliber and experience is key to achieving our goal of becoming the leader in remote cardiac monitoring in the U.S. market. Jon brings extensive experience in the CRM/EP market and a proven track record of scaling startup companies and building commercial teams. We look forward to his guidance and expertise as we continue to build on our successes and provide healthcare professionals nationwide with more effective solutions for managing heart disease.”.
Implicity is a digital medtech software company that produces a platform that collects and standardizes data from a variety of implantable cardiac devices from different companies.
(Sept. 27, 2023); Implicity; Implicity Expands Senior Leadership Team with New US Chief Commercial Officer; https://www.prnewswire.com/news-releases/implicity-expands-senior-leadership-team-with-new-us-chief-commercial-officer-301939282.html
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.